These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

956 related items for PubMed ID: 1141431

  • 1. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH, Lambert PH, Miescher PA.
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [Abstract] [Full Text] [Related]

  • 2. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
    Horigome I, Seino J, Sudo K, Kinoshita Y, Saito T, Yoshinaga K.
    Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827
    [Abstract] [Full Text] [Related]

  • 3. Metabolism of properdin in normal subjects and patients with renal disease.
    Ziegler JB, Rosen FS, Alper CA, Grupe W, Lepow IH.
    J Clin Invest; 1975 Sep; 56(3):761-7. PubMed ID: 1159085
    [Abstract] [Full Text] [Related]

  • 4. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D, Williams DG.
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [Abstract] [Full Text] [Related]

  • 5. The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis.
    Garin EH, Donnelly WH, Shulman ST, Fernandez R, Finton C, Williams RL, Richard GA.
    Clin Nephrol; 1979 Oct; 12(4):148-55. PubMed ID: 315852
    [Abstract] [Full Text] [Related]

  • 6. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP, Pertosa G, Stanziale P, Vox E, Pecoraro C, Andreucci VE.
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [Abstract] [Full Text] [Related]

  • 7. [Activation of the complement system in different forms of glomerulonephritis].
    Wegmüller E, Frey B, Hodler J.
    Schweiz Med Wochenschr; 1977 Jul 23; 107(29):1028-34. PubMed ID: 331469
    [Abstract] [Full Text] [Related]

  • 8. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
    Ruley EJ, Forristal J, Davis NC, Andres C, West CD.
    J Clin Invest; 1973 Apr 23; 52(4):896-904. PubMed ID: 4693654
    [Abstract] [Full Text] [Related]

  • 9. Studies of serum complement in the hypocomplementaemic nephritides.
    Williams DG, Peters DK, Fallows J, Petrie A, Kourilsky O, Morel-Maroger L, Cameron JS.
    Clin Exp Immunol; 1974 Nov 23; 18(3):391-405. PubMed ID: 4219908
    [Abstract] [Full Text] [Related]

  • 10. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
    Geiger H, Good RA, Day NK.
    Clin Nephrol; 1975 Nov 23; 3(4):139-47. PubMed ID: 1149337
    [Abstract] [Full Text] [Related]

  • 11. Serum and glomerular complement in 205 cases of glomerulonephritis.
    Durante A, Rovati C, di Belgiojoso GB, Minetti L.
    Proc Eur Dial Transplant Assoc; 1976 Nov 23; 12():189-96. PubMed ID: 935112
    [Abstract] [Full Text] [Related]

  • 12. Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis.
    Andres GA, Accinni L, Beiser SM, Christian CL, Cinotti GA, Erlanger BF, Hsu KC, Seegal BC.
    J Clin Invest; 1970 Nov 23; 49(11):2106-18. PubMed ID: 4097660
    [Abstract] [Full Text] [Related]

  • 13. Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
    Kim Y, Miller K, Michael AF.
    J Lab Clin Med; 1977 Apr 23; 89(4):845-50. PubMed ID: 845484
    [Abstract] [Full Text] [Related]

  • 14. Determination of complement breakdown fragments C3d and its subfragments in health and disease.
    Tamotsu M, Arai K, Fujita S, Hosotsubo K, Hayashi C, Miyai K, Miyano A, Kawanaka K, Takenaka M, Shimizu A.
    Diagn Immunol; 1984 Apr 23; 2(2):116-21. PubMed ID: 6333963
    [Abstract] [Full Text] [Related]

  • 15. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE.
    J Clin Lab Immunol; 1988 Jun 23; 26(2):73-9. PubMed ID: 3264027
    [Abstract] [Full Text] [Related]

  • 16. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
    Arroyave CM, Wilson MR, Tan EM.
    J Immunol; 1976 Mar 23; 116(3):821-6. PubMed ID: 815434
    [Abstract] [Full Text] [Related]

  • 17. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ.
    J Immunol; 1985 Sep 23; 135(3):2005-14. PubMed ID: 4020137
    [Abstract] [Full Text] [Related]

  • 18. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T, Fujita T, Kono I, Kabashima T, Yamane K, Tamura N, Kashiwagi H.
    Clin Exp Immunol; 1982 Apr 23; 48(1):37-42. PubMed ID: 6979449
    [Abstract] [Full Text] [Related]

  • 19. Activation of the alternative complement pathway in systemic lupus erythematosus.
    Wilson MR, Arroyave CM, Nakamura RM, Vaughan JH, Tan EM.
    Clin Exp Immunol; 1976 Oct 23; 26(1):11-20. PubMed ID: 826360
    [Abstract] [Full Text] [Related]

  • 20. Reduction of phagocyte adherence by nephritic sera: relation to complement activation.
    Strife CF, Ruley EJ.
    Pediatr Res; 1984 Jul 23; 18(7):637-42. PubMed ID: 6332298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.